Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03824691
Title hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Indications

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Cabozantinib + Durvalumab

Age Groups: senior | adult
Covered Countries


No variant requirements are available.